AIDS最新文献

{"title":"Clinical implications of the new definition of obesity among persons with HIV.","authors":"Allie R Walpert, Teressa S Thomas, Eva Sanchez, Mansi Gupta, Hang Lee, Michael T Lu, Wd Francois Venter, Jennifer Manne-Goehler, Suman Srinivasa","doi":"10.1097/QAD.0000000000004571","DOIUrl":"10.1097/QAD.0000000000004571","url":null,"abstract":"<p><strong>Objective: </strong>A new definition of obesity places emphasis on anthropometrics rather than BMI. We explored how people with HIV (PWH) shifted categories when using the new definition of obesity and the association with subclinical cardiovascular disease (CVD).</p><p><strong>Design: </strong>A secondary data analysis of a cross-sectional and longitudinal cohort from a completed trial focused on CVD among PWH.</p><p><strong>Methods: </strong>Obesity was defined as two measures of abnormal anthropometrics, or one measure of abnormal anthropometrics and a BMI at least 30 kg/m 2 , or BMI at least 40 kg/m 2 . Obesity was further classified as clinical obesity if there was evidence of a clinical manifestation.</p><p><strong>Results: </strong>45% (33/74) vs. 78% (58/74) of PWH were categorized as having obesity based on the old vs. new definitions for obesity. Among PWH with BMI less than 30 kg/m 2 , 61% (25/41) were reclassified as having obesity based on the new definition. The proportion with coronary artery calcium (CAC) score more than 0 was increased among the clinical vs. preclinical obesity groups (83 vs. 50%). A higher proportion with CAC more than 0 was also detected comparing clinical obesity vs. the old definition of obesity (83 vs. 71%). In the longitudinal analysis, among those randomized to placebo in the parent study, CAC increased over a 12-month period among 100% with clinical obesity vs. 36% with preclinical obesity ( P  = 0.006). Change in CAC score was higher in the clinical vs. preclinical obesity group [9(6, 197) vs. 0(0, 5), P  = 0.02].</p><p><strong>Conclusion: </strong>The new definition recategorizes more PWH with obesity not previously considered to have obesity using BMI alone, which may be useful for capturing those with abdominal adiposity. In addition, the recategorization may also have clinical implications for detecting more subclinical CVD.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1668-1673"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV-associated neurocognitive disorders, among adolescents with HIV in India.","authors":"Mishali Bhattacharjee, Nicole Phillips, Leigh Schrieff-Brown, Jackie Hoare, Marilyn Lake, Kevin Thomas","doi":"10.1097/QAD.0000000000004586","DOIUrl":"10.1097/QAD.0000000000004586","url":null,"abstract":"<p><strong>Background: </strong>Research on neurocognition among Indian adolescents with HIV (AHIV) has only recently begun to emerge, with earlier studies predominantly focusing on adult cohorts or international populations.</p><p><strong>Objective: </strong>This study examined neurocognitive functioning in adolescents aged 11-16 years from Bengaluru, Karnataka, comparing perinatally infected AHIV with healthy controls.</p><p><strong>Design and methods: </strong>This cross-sectional study investigated HIV-associated neurocognitive disorder (HAND) in 148 participants, 70 perinatally infected AHIV and 78 controls. Participants completed a neurocognitive battery assessing eight domains: attention, processing speed, verbal memory, visual memory, visual-spatial memory, language, motor coordination, and executive functioning.</p><p><strong>Results: </strong>AHIV performed significantly worse than controls across all assessed domains, reflecting widespread and multidomain cognitive vulnerability during adolescence. Significant impairments were observed in attention (estimate = -0.83, P  < 0.001), processing speed (estimate = -0.81, P  < 0.001), executive functioning (estimate = -0.82, P  < 0.001), language (estimate = -0.68, P  < 0.001), verbal memory (estimate = -0.46, P  < 0.001), motor coordination (estimate = -0.46, P  < 0.001), and visual memory (estimate = -0.29, P  < 0.001). The assessment battery, originally validated in South Africa, demonstrated reliability (Cronbach's α ranging from 0.67 to 0.88) and cultural sensitivity through rigorous translation and back-translation procedures, supporting its cross-cultural applicability in the Indian context.</p><p><strong>Conclusion: </strong>Neurocognitive impairment remains a persistent and clinically meaningful outcome of perinatal HIV infection despite antiretroviral therapy, underscoring the urgent need for standardized neurocognitive assessment and early intervention for AHIV in low- and middle-income country (LMIC) settings.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1634-1641"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitavastatin effect on enterocyte injury markers in an antiretroviral therapy-treated HIV population.","authors":"Aya Awwad, Upasana Das Adhikari, Tricia H Burdo, Stephen Baak, Miloni S Dalal, Carl J Fichtenbaum, Markella V Zanni, Judith A Aberg, Judith S Currier, Gerald S Bloomfield, Sarah M Chu, Alex B Lu, Pamela S Douglas, Heather J Ribaudo, Douglas S Kwon, Steven K Grinspoon","doi":"10.1097/QAD.0000000000004572","DOIUrl":"10.1097/QAD.0000000000004572","url":null,"abstract":"<p><strong>Objective: </strong>To determine whether pitavastatin reduces enterocyte injury, assessed by intestinal fatty acid-binding protein (I-FABP), among antiretroviral therapy-treated people with HIV (PWH) enrolled in the REPRIEVE mechanistic substudy.</p><p><strong>Design: </strong>Randomized, double-blind, placebo-controlled trial.</p><p><strong>Methods: </strong>We analyzed fasting plasma I-FABP at entry and month 24 among participants randomized to pitavastatin 4 mg daily or placebo. Baseline characteristics were summarized across I-FABP quartiles. Associations between entry I-FABP and inflammatory and immune activation biomarkers were assessed using Spearman correlations. Longitudinal changes were evaluated using intention-to-treat and per-protocol analyses and generalized estimating equation models.</p><p><strong>Results: </strong>Among 710 participants with entry I-FABP measurements (median age 50 years; 18.5% women; 98% with undetectable viral load), median I-FABP levels were 2690 (Q1-Q3: 1888-3770) (pg/ml). Entry I-FABP correlated modestly with markers of systemic inflammation and monocyte activation, including GDF-15 and soluble CD14 + . Over 24 months, I-FABP levels declined similarly in the pitavastatin and placebo arms, with no significant differences in absolute or fold change.</p><p><strong>Conclusion: </strong>In this well treated HIV cohort, higher baseline I-FABP levels were associated with increased inflammatory markers at study entry. However, pitavastatin did not reduce I-FABP over follow-up. These findings suggest that the cardiovascular benefit of pitavastatin in REPRIEVE is unlikely to be mediated through reductions in enterocyte injury, although gut-barrier effects of other statins cannot be excluded.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1674-1680"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148325315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered bile acid metabolism in people with HIV correlates with systemic and intestinal inflammation.","authors":"Sophie Irwin, Julie Elliott, Fan Li, Paola Ruiz, Peter A Anton, Xiaotang Du, Jennifer A Fulcher","doi":"10.1097/QAD.0000000000004585","DOIUrl":"10.1097/QAD.0000000000004585","url":null,"abstract":"<p><strong>Objective: </strong>To examine associations between plasma bile acids, systemic and gut inflammation, and intestinal bile acid receptor expression in people with HIV (PWH).</p><p><strong>Design: </strong>Retrospective case-control study using paired plasma and colorectal biopsy samples from adults with and without HIV.</p><p><strong>Methods: </strong>Samples from 31 PWH and 21 people without HIV (PWOH) were analyzed. Plasma bile acids were quantified by targeted liquid chromatography-mass spectrometry (LC-MS) and cytokines by multiplex assays. Bile acid receptors farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) were quantified in gut tissue by quantitative reverse-transcriptase (qRT)-PCR, and immunohistochemistry with digital image analysis to localize receptor expression. Intestinal inflammation was assessed by histopathology. Group comparisons, multivariable regression, and Pearson correlations were used to evaluate relationships among bile acids, inflammation, and receptor expression.</p><p><strong>Results: </strong>Decreased levels of the primary bile acid chenodeoxycholic acid [ P  < 0.001, false discovery rate (FDR) = 0.002] as well as decreased levels of conjugated secondary bile acids glycochenodeoxycholic acid ( P  < 0.001, FDR=0.001), and taurochenodeoxycholic acid ( P  = 0.007, FDR = 0.02), and glycoursodeoxycholic acid ( P  = 0.008, FDR = 0.02) were observed in PWH. Antiretroviral therapy may also be a contributor to bile acid alterations with decreased glycodeoxycholic acid ( P  = 0.02, FDR = 0.19). There was no difference in FXR expression in the gut, but PWH had higher TGR5 expression ( P  < 0.001), which correlated with intestinal inflammation histopathology scores ( r  = 0.56, P  = 0.004).</p><p><strong>Conclusion: </strong>PWH had decreased plasma primary and secondary bile acids. In addition, PWH had higher TGR5 expression in the gut, which correlated with intestinal inflammation. Reduced anti-inflammatory bile acid signaling may be one potential mechanism contributing to ongoing inflammation in HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1602-1611"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV-associated pulmonary arterial hypertension: improving survival despite persistent treatment gaps - a systematic review and meta-analysis.","authors":"Marcos Vinicius Fernandes Garcia, Tim Lahm","doi":"10.1097/QAD.0000000000004595","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004595","url":null,"abstract":"<p><p>HIV-associated pulmonary arterial hypertension (HIV-PAH) is rare and understudied. We pooled 12 right heart catheterization-confirmed cohorts (n = 537, 1986-2021) and found that HIV-PAH presents with severe hemodynamics and advanced functional limitation, with only 64% receiving PAH-targeted therapy at diagnosis. Survival improved progressively over three decades alongside increasing therapy use. These findings highlight persistent treatment gaps and support consideration of contemporary combination PAH therapy in people with HIV-PAH.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 11","pages":"1773-1776"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carotid inflammation on FDG-PET is associated with lower cognitive performance in people with treated HIV infection.","authors":"Meg Wilson, Alaa Abdellatif, Shady Abohashem, Elissa S Epel, Ahmed Tawakol, Priscilla Y Hsue, Felicia C Chow","doi":"10.1097/QAD.0000000000004573","DOIUrl":"10.1097/QAD.0000000000004573","url":null,"abstract":"<p><strong>Objectives: </strong>Carotid atherosclerosis is an established risk factor for cognitive impairment. FDG-PET detects subtle inflammatory changes in the arterial wall that may precede plaque formation and rupture. We investigated whether carotid inflammation is associated with cognitive function and its relative importance as a predictor of concurrent cognitive function compared with other factors.</p><p><strong>Design/methods: </strong>: In this cross-sectional study, we recruited individuals ≥40 years with undetectable viral load at moderate-to-high cardiovascular risk. Participants underwent FDG-PET, stress and cognitive assessments. We used pairwise partial correlations to identify significant associations between arterial inflammation and cognition. We applied a machine learning analysis workflow to evaluate the ability of carotid inflammation alone, and in combination with other factors, to predict cognition.</p><p><strong>Results: </strong>Among 47 people, carotid inflammation was independently correlated with global cognition [ r  = -0.405, 95% confidence interval (CI) -0.618 to -0.100, P  = 0.007]. In the machine learning analysis, the probability of carotid inflammation predicting cognitive function within one standard deviation of the true value was 68% (95% CI 52-80). The predictive accuracy improved marginally when individual cardiometabolic factors were added to the model (73%, 95% CI 57-84). When all potential variables were considered, predictive accuracy improved substantially (85%, 95% CI 71-93), with carotid inflammation remaining as the most important cardiometabolic predictor of cognitive function.</p><p><strong>Conclusion: </strong>Carotid inflammation on FDG-PET outperformed most other factors in predicting concurrent cognitive function and provided unique predictive information beyond traditional cardiometabolic risk factors. Future longitudinal studies should examine whether carotid inflammation predicts incident cognitive impairment, which would support its use as a clinical risk marker in people with HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1624-1633"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV-1 soluble gp120 in cerebrospinal fluid is associated with poorer motor domain neurocognitive performance in virally suppressed people with HIV.","authors":"Mehdi Benlarbi, Mohammadsobhan S Andalibi, Étienne Bélanger, Alexandra Tauzin, Katrina Dionne, Monika Chandravanshi, Halima Medjahed, Catherine Bourassa, William D Tolbert, Marzena Pazgier, Madeleine Durand, Andrés Finzi, Ronald J Ellis","doi":"10.1097/QAD.0000000000004578","DOIUrl":"10.1097/QAD.0000000000004578","url":null,"abstract":"<p><strong>Background: </strong>Despite effective antiretroviral therapy (ART), neurocognitive impairment (NCI) persists in 30-50% of virally suppressed (VS) people with HIV. The mechanisms underlying this persisting NCI remain incompletely understood. Soluble gp120 (sgp120) has been detected in the plasma of people with HIV on ART and may contribute to inflammation and CD4 + T-cell depletion in the presence of non-neutralizing anti-cluster A antibodies (Abs). gp120 can induce neurotoxicity, leading to neuronal damage both in vitro and in transgenic mice.</p><p><strong>Objective: </strong>To determine whether sgp120 and anti-cluster A Abs are detectable in the cerebrospinal fluid (CSF) of VS people with HIV and to evaluate whether their presence is associated with domain-specific neurocognitive performance.</p><p><strong>Methods: </strong>We analyzed paired plasma and CSF samples from 146 VS people with HIV and 37 unsuppressed people with HIV. Neurocognitive performance was assessed using a comprehensive neuropsychological testing battery across multiple domains, from which demographically adjusted T -scores for each test were derived. Levels of sgp120 and anti-cluster A Abs were measured to evaluate their association with neurocognitive performance in people with HIV.</p><p><strong>Results: </strong>Sgp120 and anti-cluster A Abs were detected in the CSF of 11% and 26% of VS people with HIV, respectively. Detection of CSF sgp120 was associated with lower neurocognitive motor-domain T -scores (Mann-Whitney U , P  = 0.039; Cliff's δ  = -0.33). This association was confined to sgp120 in the CSF and was not observed for sgp120 in plasma or for anti-HIV antibodies in the CSF.</p><p><strong>Conclusion: </strong>These findings suggest that central nervous system (CNS) exposure to sgp120 may contribute to poorer motor neurocognitive performance in VS people with HIV. Strategies targeting CSF sgp120-related biomarkers warrant further investigation as potential approaches to mitigate NCI in VS people with HIV.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1591-1601"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive trajectories in HIV: looking beyond the virus to preserve brain health.","authors":"Jaime H Vera","doi":"10.1097/QAD.0000000000004601","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004601","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 11","pages":"1762-1764"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An inclusive approach for developing global clinical trial recommendations.","authors":"Victoria O Kasprowicz, Steven G Deeks, William Kilembe, Krista L Dong, Lydie Trautmann, Mark F Cotton, Karine Dubé, Donn J Colby, Trevor A Crowell, Philip J Goulder, Randall Tressler, Moses Nsubuga, Sharon R Lewin, Thandi M Onami, Thumbi Ndung'u","doi":"10.1097/QAD.0000000000004582","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004582","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 11","pages":"1765-1768"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD4 + cell count trends after common cancers in people with HIV: a multicohort collaboration.","authors":"Alisa Timiryasova, Lauren Greenberg, Pere Domingo, Philip E Tarr, Alexander Egle, Charlotte Martin, Cristina Mussini, Ferdinand Wit, Antonella Cingolani, Clara Lehmann, Antonella Castagna, Kathy Petoumenos, Caroline A Sabin, Alvaro Borges, Wafaa El-Sadr, Jens Lundgren, Sean Hosein, Christina Carlander, Alain Amstutz, Katharina Grabmeier-Pfistershammer, Harmony Garges, Andrea Marongui, Lital A Young, Lars Peters, Lene Ryom","doi":"10.1097/QAD.0000000000004579","DOIUrl":"10.1097/QAD.0000000000004579","url":null,"abstract":"<p><strong>Objective: </strong>Whilst cancer is increasingly common in people with HIV, insight into immunological outcomes after cancer diagnosis (CaD) is limited. European guidelines recommend opportunistic infection prophylaxis (OIP) at CD4 + cell count of less than 200 cells/μl, and during chemotherapy/radiotherapy regardless of CD4 + cell count. We assessed CD4 + cell count trends and predictors of post-CaD immunosuppression across common cancers.</p><p><strong>Design: </strong>Participants from D:A:D and RESPOND with Kaposi's sarcoma, non-Hodgkin lymphoma (NHL), lung, anal or prostate cancer and at least two CD4 + cell count measurements at 6-12 months post-CaD were included.</p><p><strong>Methods: </strong>CD4 + cell count measurements were evaluated at 6-monthly intervals. Logistic regression models with generalized estimating equations assessed predictors of CD4 + cell count of less than 200 up to 3 years post-CaD.</p><p><strong>Results: </strong>Among 1670 individuals (9597 person-years of follow-up, median 5.3 years), 89% were male, median age was 51 years [interquartile range (IQR) 42-60] and median CD4 + cell count of 400 cells/μl (288-590) at CaD. The highest proportion of participants with CD4 + cell count of less than 200 cells/μl was at time of CaD for Kaposi's sarcoma (36%), at 6 months post-CaD for NHL and anal cancer (40% and 30% respectively), at 12 months post-CaD for lung (17%) and 18 months post-CaD for prostate cancer (7%). Higher CD4 + cell count at CaD was associated with lower odds of CD4 + cell count of less than 200 post-CaD [200-350: 0.12 (95% confidence interval 0.08-0.16); 350-500: 0.05 (0.03-0.07); >500: 0.02 (0.02-0.04), vs. <200]. Other predictors included disseminated disease, anal cancer, injection drug use as HIV acquisition mode and male gender/sex; age and calendar time were not predictive.</p><p><strong>Conclusion: </strong>As post-CaD immunosuppression trends varied by several factors including cancer type, and CD4 + cell count at CaD, individualized use of opportunistic infection prophylaxis may be considered when regular CD4 + cell count monitoring is available.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1681-1689"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}